
    
      Patients planned for randomization: 91 patients in the eptinezumab 100 mg group and 91
      patients in the placebo group.

      The total study duration from the Screening Visit to the Safety Follow-up Visit is
      approximately 36 weeks and includes a Screening Period (28-30 days), a Placebo-controlled
      Period (12 weeks), an Open-Label Period (12 weeks) and a Safety Follow-up Period (8 weeks).
      Patient will receive investigational medicinal product (IMP) at the Baseline Visit with
      either eptinezumab or placebo by IV infusion and at week 12 visit.
    
  